CARLSBAD,
Calif.—August 16, 2012 (MARKET WIRE)-- International Stem Cell Corporation
(OTCQB: ISCO) (www.internationalstemcell.com) (“ISCO” or “the
Company”) a California-based biotechnology company focused on therapeutic and
research products, today announced the addition of Professor Evan Snyder* and
Dr. Rosasio Sánchez‐Pernaute as scientific advisors on our Parkinson’s disease
program.
Evan
Snyder MD, PhD is a Professor at the Sanford
Burnham Medical Research Institute and director of Sanford-Burnham’s
stem cell program and research center. Prof.
Snyder is regarded as one of the pioneers of stem cell research, particularly
with regard to regenerative medicine applications. He is an expert on Parkinson’s disease (PD), one
of the first scientists to identify neural stem cells and to document the ability
of stem cells to migrate to injured or diseased regions of the brain. Prof. Snyder is a recipient of an Early
Translational Award from the California Institute for Regenerative Medicine
(CIRM) to research into cell based therapies for PD.
Rosario
Sánchez‐Pernaute, MD, PhD. is an internationally recognized expert on the use
of stem cells to treat Parkinson’s disease.
While Assistant Professor in Neurology at Harvard Medical School Dr. Sánchez‐Pernaute
was one of the first scientists to demonstrate the possibility of using
parthenogenetic stem cells to treat the causes of PD in a non-human primate
model.
“We
are extremely fortunate to work with two of the world’s leading experts in
Parkinson’s disease and stem cell research”, say Dr. Ruslan Semechkin, Vice
President of Research and Development, “Prof. Snyder and Dr. Sánchez‐Pernaute
will add invaluable expertise to our Parkinson’s disease program and provide
input into our first non-human primate pre-clinical study which uses the most
reliable and predictive model of Parkinson’s in humans.”
*Prof.
Snyder’s position is honorary.
About International
Stem Cell Corporation
International
Stem Cell Corporation is focused on the therapeutic applications of human
parthenogenetic stem cells (hpSCs) and the development and commercialization of
cell-based research and cosmetic products. ISCO's core technology, parthenogenesis,
results in the creation of pluripotent human stem cells from unfertilized
oocytes (eggs). hpSCs avoid ethical
issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first
parthenogenetic, homozygous stem cell line that can be a source of therapeutic
cells for hundreds of millions of individuals of differing genders, ages and
racial background with minimal immune rejection after transplantation. hpSCs
offer the potential to create the first true stem cell bank, UniStemCell™. ISCO
also produces and markets specialized cells and growth media for therapeutic
research worldwide through its subsidiary Lifeline Cell Technology
(www.lifelinecelltech.com), and stem cell-based skin care products through its
subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is
available at www.internationalstemcell.com.
To
subscribe to receive ongoing corporate communications, please click on the
following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
Safe harbor statement
Statements
pertaining to anticipated developments, scientific program and clinical
development goals and plans and other opportunities for the company and its
subsidiaries, along with other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such as
"will," "believes," "plans,"
"anticipates," "expects," "estimates,") should
also be considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks inherent
in the development and/or commercialization of potential products and the
management of collaborations, regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing uses, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements and
as such should be evaluated together with the many uncertainties that affect
the company's business, particularly those mentioned in the cautionary
statements found in the company's Securities and Exchange Commission filings.
The company disclaims any intent or obligation to update forward-looking
statements.
